Editas Medicine Toekomstige groei
Future criteriumcontroles 1/6
De winst van Editas Medicine zal naar verwachting dalen met 0.3% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 15.2% per jaar. De winst per aandeel zal naar verwachting groeien met 13.8% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -187.5% zijn.
Belangrijke informatie
-0.3%
Groei van de winst
13.8%
Groei van de winst per aandeel
Biotechs winstgroei | 28.4% |
Inkomstengroei | 15.2% |
Toekomstig rendement op eigen vermogen | -187.5% |
Dekking van analisten | Good |
Laatst bijgewerkt | 08 Nov 2024 |
Recente toekomstige groei-updates
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 10Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results
May 12Recent updates
Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding
Nov 20Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week
Nov 06Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Sep 26Editas Medicine: A Risk/Reward Worth Considering
Sep 25Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet
Aug 23Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 10Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results
May 12The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%
Apr 23Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Mar 09Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)
Dec 15Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
May 10Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Jan 19Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline
Oct 18Editas Medicine started at neutral at BofA due to competition in gene editing programs
Sep 29We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely
Sep 13Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies
Aug 23Editas Medicine Q2 2022 Earnings Preview
Aug 02Baisong Mei joins Editas Medicine as Chief Medical Officer
Jul 18Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?
Jun 12Editas: Tackling Rare Eye Disease With Use Of Crispr Technology
Jun 06Editas: The Unforeseen Detrimental Effect Of Patent Win
Mar 25Editas: CRISPR Gene Editing Biotech With Promising Future
Mar 15Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 20 | -253 | -225 | -224 | 13 |
12/31/2025 | 27 | -243 | -215 | -210 | 18 |
12/31/2024 | 41 | -221 | -150 | -143 | 18 |
9/30/2024 | 62 | -211 | -191 | -182 | N/A |
6/30/2024 | 67 | -193 | -172 | -165 | N/A |
3/31/2024 | 69 | -166 | -151 | -146 | N/A |
12/31/2023 | 78 | -153 | -137 | -132 | N/A |
9/30/2023 | 25 | -195 | -156 | -152 | N/A |
6/30/2023 | 19 | -206 | -169 | -165 | N/A |
3/31/2023 | 23 | -219 | -168 | -164 | N/A |
12/31/2022 | 20 | -220 | -181 | -177 | N/A |
9/30/2022 | 26 | -201 | -176 | -170 | N/A |
6/30/2022 | 32 | -184 | -171 | -162 | N/A |
3/31/2022 | 26 | -186 | -174 | -164 | N/A |
12/31/2021 | 26 | -193 | -172 | -164 | N/A |
9/30/2021 | 24 | -214 | -176 | -169 | N/A |
6/30/2021 | 81 | -167 | -189 | -183 | N/A |
3/31/2021 | 92 | -135 | -180 | -175 | N/A |
12/31/2020 | 91 | -116 | -187 | -180 | N/A |
9/30/2020 | 92 | -91 | -106 | -99 | N/A |
6/30/2020 | 33 | -132 | -79 | -71 | N/A |
3/31/2020 | 24 | -142 | -73 | -66 | N/A |
12/31/2019 | 21 | -134 | -47 | -41 | N/A |
9/30/2019 | 14 | -121 | -86 | -80 | N/A |
6/30/2019 | 25 | -103 | -66 | -61 | N/A |
3/31/2019 | 30 | -108 | -57 | -52 | N/A |
12/31/2018 | 32 | -110 | -50 | -46 | N/A |
9/30/2018 | 29 | -121 | -76 | -72 | N/A |
6/30/2018 | 21 | -132 | N/A | -92 | N/A |
3/31/2018 | 17 | -120 | N/A | -102 | N/A |
12/31/2017 | 14 | -120 | N/A | -9 | N/A |
9/30/2017 | 11 | -124 | N/A | 2 | N/A |
6/30/2017 | 6 | -118 | N/A | 13 | N/A |
3/31/2017 | 6 | -111 | N/A | 29 | N/A |
12/31/2016 | 6 | -97 | N/A | -50 | N/A |
9/30/2016 | 6 | -71 | N/A | -45 | N/A |
6/30/2016 | 6 | -57 | N/A | -39 | N/A |
3/31/2016 | 2 | -86 | N/A | -9 | N/A |
12/31/2015 | 2 | -73 | N/A | -5 | N/A |
9/30/2015 | 1 | -66 | N/A | -1 | N/A |
6/30/2015 | 0 | -62 | N/A | 9 | N/A |
3/31/2015 | N/A | -17 | N/A | -13 | N/A |
12/31/2014 | N/A | -14 | N/A | -9 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat EDIT de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat EDIT de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat EDIT de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van EDIT ( 15.2% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).
Hoge groei-inkomsten: De omzet van EDIT ( 15.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat EDIT binnen 3 jaar verliesgevend zal zijn.